Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cells

被引:12
作者
Zhuge, Xin
Arai, Hidenori
Xu, Yang
Murayama, Toshinorl
Kobayashi, Takuya
Narumiya, Shuh
Kita, Toru
Yokode, Masayuki
机构
[1] Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Clin Innovat Med, Sakyo Ku, Kyoto 6068507, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068507, Japan
关键词
thromboxane A2 receptor; macrophage; atherosclerosis; apolipoprotein E-deficient mice;
D O I
10.1016/j.bbrc.2006.10.121
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the previous study, we generated mice lacking thromboxane A2 receptor (TP) and apolipoprotein E, apoE(-/-)TP(-/-) mice, and reported that the double knockout mice developed markedly smaller atherosclerotic lesions than those in apoE(-/-) mice. To investigate the mechanism responsible for reduced atherosclerosis in apoE(-/-)TP(-/-) mice, we examined the role of TP in bone marrow (BM)-derived cells in the development of the atherosclerotic lesions. When we compared the function of macrophages in apoE(-/-) and in apoE(-/-)TP(-/-) mouse in vitro, there was no difference in the expression levels of cytokines and chemokines after stimulation with lipopolysaccharide. We then transplanted the BM from either apoE(-/-) or apoE(-/-)TP(-/-) mice to either apoE(-/-) or apoE(-/-)TP(-/-) mice after sublethal irradiation. After 12 weeks with high fat diet, we analyzed the atherosclerotic lesion of aortic sinus. When the BM from apoE(-/-) or apoE(-/-)TP(-/-) mice was transplanted to apoE(-/-) mice, the lesion size was almost the same as that of apoE(-/-) mice without BM transplantation. In contrast, when the BM from apoE(-/-) or apoE(-/-)TP(-/-) mice was transplanted to apoE(-/-)TP(-/-) mice, the lesion size was markedly reduced. These results indicate that the protection of atherogenesis in TP-/- mice is not associated with TP in BM-derived cells. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:865 / 871
页数:7
相关论文
共 43 条
[1]   Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration [J].
Ashton, AW ;
Ware, JA .
CIRCULATION RESEARCH, 2004, 95 (04) :372-379
[2]   Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice [J].
Babaev, VR ;
Ding, L ;
Reese, J ;
Morrow, JD ;
Breyer, MD ;
Dey, SK ;
Fazio, S ;
Linton, MF .
CIRCULATION, 2006, 113 (01) :108-117
[3]   Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin [J].
Belhassen, L ;
Pelle, G ;
Dubois-Rande, JL ;
Adnot, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1198-1204
[4]   The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice - Evidence that eicosanoids other than thromboxane contribute to atherosclerosis [J].
Cayatte, AJ ;
Du, Y ;
Oliver-Krasinski, J ;
Lavielle, G ;
Verbeuren, TJ ;
Cohen, RA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (07) :1724-1728
[5]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541
[6]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205
[7]   ANTIPLATELET THERAPY FOR THROMBOPROPHYLAXIS - THE NEED FOR CAREFUL CONSIDERATION OF THE EVIDENCE FROM RANDOMIZED TRIALS [J].
COLLINS, R ;
BAIGENT, C ;
SANDERCOCK, P ;
PETO, R .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 309 (6963) :1215-1217
[8]   Cyclooxygenases, thromboxane, and atherosclerosis -: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism [J].
Egan, KM ;
Wang, M ;
Lucitt, MB ;
Zukas, AM ;
Puré, E ;
Lawson, JA ;
FitzGerald, GA .
CIRCULATION, 2005, 111 (03) :334-342
[9]   THROMBOXANE SYNTHASE INHIBITORS, THROMBOXANE RECEPTOR ANTAGONISTS AND DUAL BLOCKERS IN THROMBOTIC DISORDERS [J].
GRESELE, P ;
DECKMYN, H ;
NENCI, GG ;
VERMYLEN, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (04) :158-163
[10]  
HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213